What is the recommended treatment approach for benign prostatic hyperplasia?

Treatment of Benign Prostatic Hyperplasia

For symptomatic BPH, alpha-blockers (tamsulosin, silodosin, alfuzosin, doxazosin, or terazosin) are the first-line medical therapy, with 5-alpha reductase inhibitors (5-ARIs) added for men with prostate volume >30cc or PSA >1.5 ng/mL to prevent disease progression. 1

Initial Management Algorithm

Mild Symptoms (IPSS 1-7)

• Watchful waiting is appropriate for men with mild symptoms who are not bothered by their condition 2, 3
• Self-management strategies and lifestyle modifications should be implemented 2

Moderate to Severe Symptoms (IPSS ≥8)

Step 1: Alpha-Blocker Monotherapy

Start with an alpha-blocker as first-line treatment 1. The most effective agents based on IPSS reduction are:

• Doxazosin (most effective: -7.06 points, ranking 1.75) 1
• Terazosin (-6.76 points, ranking 2.42) 1
• Silodosin (-6.55 points, ranking 3.70) 1
• Tamsulosin (-5.83 points, ranking 5.03) 1
• Alfuzosin (-5.46 points, ranking 6.92) 1

All alpha-blockers work within days to weeks, providing rapid symptom relief 1. The choice between agents depends on side effect profiles rather than efficacy differences.

Critical Caveat: Men scheduled for cataract surgery should avoid tamsulosin due to intraoperative floppy iris syndrome risk 2. Inform ophthalmologists of alpha-blocker use.

Step 2: Add 5-ARI for Appropriate Candidates

Add a 5-ARI (finasteride or dutasteride) to alpha-blocker therapy when:

• Prostate volume >30cc (confirmed by imaging or DRE) 1
• PSA >1.5 ng/mL 1
• Goal is to prevent acute urinary retention and reduce need for future surgery 2

5-ARI Selection:

• Dutasteride inhibits both type I and II 5-alpha reductase (95% DHT reduction) 1
• Finasteride inhibits only type II (70% DHT reduction) 1
• Both reduce prostate volume by 15-25% at 6 months 1
• Symptom improvement is slow (months), so counsel patients accordingly 1

PSA Monitoring on 5-ARIs: After 1 year of therapy, double the measured PSA value when screening for prostate cancer, as 5-ARIs reduce PSA by approximately 50% 1. The free/total PSA ratio remains constant 1.

Step 3: Consider Adjunctive Therapy

For persistent storage symptoms despite alpha-blocker ± 5-ARI:

• Tadalafil (PDE-5 inhibitor): -5.26 IPSS points, ranking 8.15 1
• May provide additional relief for "bothersome" symptoms 4
• Beta-3 agonists (mirabegron): emerging evidence for storage symptom relief 4

Avoid antimuscarinics unless absolutely necessary—they rank poorly (tolterodine: -4.25 points, ranking 11.61; solifenacin: -3.69 points, ranking 12.27) 1

Surgical Intervention Indications

Absolute indications for surgery (medical therapy failure):

• Refractory urinary retention
• Recurrent urinary tract infections
• Bladder stones
• Renal insufficiency due to BPH
• Gross hematuria refractory to medical therapy
• Failure of medical management with persistent bothersome symptoms 3

Surgical options should be matched to prostate size, patient characteristics, and surgeon expertise 5:

• TURP remains gold standard
• HoLEP for larger glands
• Robot-assisted simple prostatectomy for very large glands (>80-100g) with excellent continence outcomes (95.5% continent within 3 months) 6
• Minimally invasive options: water vapor thermal therapy (Rezum), prostatic urethral lift (UroLift), prostate artery embolization 5, 7, 8

Acute Urinary Retention Management

When AUR occurs:

1. Catheterize immediately (urethral or suprapubic based on contraindications) 9
2. Start alpha-blocker (alfuzosin 10mg, tamsulosin 0.4mg, or silodosin 8mg) for 2-3 days 9
3. Trial without catheter after <3-5 days of catheterization 9
4. Short catheterization duration reduces complications without compromising success rates 9

Perioperative 5-ARI Use: Consider starting 5-ARIs 2-4 weeks before TURP or other BPH surgery to reduce intraoperative bleeding and transfusion risk 1

Common Pitfalls

• Not obtaining prostate volume before starting 5-ARIs—these drugs are ineffective in smaller glands (<30cc) 1
• Expecting rapid results from 5-ARIs—counsel patients about 6-12 month timeline for maximal benefit 1
• Forgetting to adjust PSA values in men on 5-ARIs during prostate cancer screening 1
• Using tamsulosin in men planning cataract surgery 2
• Prolonged catheterization after AUR (>5 days increases complications) 9